David Westenberg
Stock Analyst at Piper Sandler
(4.55)
# 275
Out of 5,042 analysts
179
Total ratings
57.28%
Success rate
21.19%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $70 → $105 | $89.23 | +17.67% | 5 | Oct 22, 2025 | |
| GH Guardant Health | Maintains: Overweight | $60 → $90 | $72.15 | +24.74% | 10 | Oct 22, 2025 | |
| NEOG Neogen | Reiterates: Neutral | $5 → $6.5 | $6.19 | +5.01% | 13 | Oct 16, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $15 → $20 | $17.22 | +16.14% | 15 | Oct 15, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $60 → $70 | $64.64 | +8.29% | 12 | Oct 8, 2025 | |
| WGS GeneDx Holdings | Maintains: Overweight | $120 → $140 | $128.87 | +8.64% | 3 | Sep 11, 2025 | |
| TXG 10x Genomics | Initiates: Neutral | $15 | $13.77 | +8.93% | 2 | Sep 11, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.25 → $1.5 | $2.02 | -25.74% | 9 | Aug 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $210 → $215 | $145.94 | +47.32% | 15 | Aug 11, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $510 → $700 | $640.85 | +9.23% | 11 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $18 | $22.05 | -18.37% | 10 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $220 | $192.51 | +14.28% | 16 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $11 | $10.67 | +3.09% | 10 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $21 | $23.72 | -11.47% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $185 | $100.11 | +84.80% | 16 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $260 → $280 | $279.49 | +0.18% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $200 | $182.18 | +9.78% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $4.26 | +87.79% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $30.51 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $43.80 | - | 1 | Nov 21, 2017 |
Tempus AI
Oct 22, 2025
Maintains: Neutral
Price Target: $70 → $105
Current: $89.23
Upside: +17.67%
Guardant Health
Oct 22, 2025
Maintains: Overweight
Price Target: $60 → $90
Current: $72.15
Upside: +24.74%
Neogen
Oct 16, 2025
Reiterates: Neutral
Price Target: $5 → $6.5
Current: $6.19
Upside: +5.01%
Adaptive Biotechnologies
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $17.22
Upside: +16.14%
Exact Sciences
Oct 8, 2025
Maintains: Overweight
Price Target: $60 → $70
Current: $64.64
Upside: +8.29%
GeneDx Holdings
Sep 11, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $128.87
Upside: +8.64%
10x Genomics
Sep 11, 2025
Initiates: Neutral
Price Target: $15
Current: $13.77
Upside: +8.93%
Pacific Biosciences of California
Aug 11, 2025
Maintains: Neutral
Price Target: $1.25 → $1.5
Current: $2.02
Upside: -25.74%
Zoetis
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $145.94
Upside: +47.32%
IDEXX Laboratories
Aug 11, 2025
Maintains: Neutral
Price Target: $510 → $700
Current: $640.85
Upside: +9.23%
Aug 11, 2025
Maintains: Neutral
Price Target: $12 → $18
Current: $22.05
Upside: -18.37%
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $220
Current: $192.51
Upside: +14.28%
Aug 4, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $10.67
Upside: +3.09%
Aug 4, 2025
Maintains: Neutral
Price Target: $23 → $21
Current: $23.72
Upside: -11.47%
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $100.11
Upside: +84.80%
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $279.49
Upside: +0.18%
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $182.18
Upside: +9.78%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $4.26
Upside: +87.79%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $30.51
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $43.80
Upside: -